These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22246626)

  • 1. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
    Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
    J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.
    Zhao X; Bose A; Komita H; Taylor JL; Kawabe M; Chi N; Spokas L; Lowe DB; Goldbach C; Alber S; Watkins SC; Butterfield LH; Kalinski P; Kirkwood JM; Storkus WJ
    Mol Ther; 2011 Apr; 19(4):805-14. PubMed ID: 21189473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
    Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
    Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice.
    Firat H; Cochet M; Rohrlich PS; Garcia-Pons F; Darche S; Danos O; Lemonnier FA; Langlade-Demoyen P
    Int Immunol; 2002 Aug; 14(8):925-34. PubMed ID: 12147629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
    Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
    Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.